Making waves and turning heads! Inomagen Therapeutics claimed 2nd place at the HRX 2025 Pitch Competition with a bold product that stood out among an incredibly strong field of innovators.

Learn more here: Inomagen Therapeutics is a preclinical-stage biotechnology company developing a non-viral gene therapy to improve the treatment of atrial fibrillation. We have demonstrated significant preclinical efficacy with our approach, which uses shRNA plasmid(s) to target key molecular mechanisms involved in the genesis of AF. To achieve targeted gene delivery, we have developed a novel transvenous gene delivery system that uses low energy electroporation to achieve high levels of gene transfection into atrial tissue. https://inomagen.com/

Want to explore more content? Catch the full video versions and more on our channel – [Heart Rhythm TV].